ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Agilent doubles down on oligonucleotides

by Rick Mullin
August 21, 2016 | APPEARED IN VOLUME 94, ISSUE 33

Agilent Technologies plans to at least double its oligonucleotide manufacturing capacity with an expansion of its plant in Frederick, Colo. The project is expected to create between 150 and 200 jobs. The instrumentation firm began its foray into nucleic acids in 2006 with the acquisition of SynPro. In 2008, it purchased Dow Chemical’s oligonucleotides business and moved it from Michigan to Colorado.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment